labetuzumab govitecan

Home
Ligands
labetuzumab govitecan

GtoPdb Ligand ID: 8252

Synonyms: hMN-14-SN-38 | hMN-14-SN-38 ADC | IMMU 130 | IMMU-130

Comment: Labetuzumab govitecan (research code IMMU-130) is an antibody-drug conjugate (ADC) in which the anti-CEACAM5 antibody labetuzumab, is covalently bound to SN-38, the active metabolite of the topoisomerase inhibitor irinotecan (as exemplified in patents [2] and [1]).

Summary
Biological activity
Clinical data
References

References
1. Govindan SV, Gale JB, Holman NJ, Goldenberg DM. (2014) Antibody-sn-38 immunoconjugates with a cl2a linker. Patent number: US20140227180. Assignee: Immunomedics, Inc.. Priority date: 13/12/2012. Publication date: 14/08/2014.
2. Govindan SV, Moon S-J,Goldenberg DM. (2014) Immunoconjugates with an intracellularly-cleavable linkage. Patent number: US8759496. Assignee: Immunomedics, Inc.. Priority date: 13/12/2002. Publication date: 24/06/2014.

References

1. Govindan SV, Gale JB, Holman NJ, Goldenberg DM. (2014)
Antibody-sn-38 immunoconjugates with a cl2a linker.
Patent number: US20140227180. Assignee: Immunomedics, Inc.. Priority date: 13/12/2012. Publication date: 14/08/2014.

2. Govindan SV, Moon S-J,Goldenberg DM. (2014)
Immunoconjugates with an intracellularly-cleavable linkage.
Patent number: US8759496. Assignee: Immunomedics, Inc.. Priority date: 13/12/2002. Publication date: 24/06/2014.